Bristol-Myers Squibb Company: Beat — EPS $1.35, Revenue $13.07B
Earnings BeatQ3 2026 · Pre-market
Did Bristol-Myers Squibb Company (BMY) beat earnings today?
Yes, Bristol-Myers Squibb Company (BMY) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+10.66% surprise
$1.35Actual
Expected: $1.22
vs. year ago -17.0%
Total Revenue+2.66% surprise
$13.07BActual
Expected: $12.73B
vs. year ago +7.0%
Released Oct 29 · 7:02 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Total Revenues | $13.07B | $12.22B | +7.0% |
| Revenue detail — reported lines | |||
| └─Net product sales | $12.61B | $11.85B | +6.4% |
| └─Alliance and other revenues | $463.00M | $372.00M | +24.5% |
| └─Opdivo | $2.37B | $2.53B | -6.0% |
| └─Opdivo Qvantig | $334.00M | $67.00M | - |
| └─Orencia | $983.00M | $964.00M | +2.0% |
| └─Yervoy | $793.00M | $739.00M | +7.0% |
| └─Reblozyl | $750.00M | $615.00M | +22.0% |
| └─Breyanzi | $526.00M | $359.00M | +46.0% |
| └─Opdualag | $367.00M | $299.00M | +23.0% |
| └─Camzyos | $420.00M | $296.00M | +42.0% |
| └─Zeposia | $168.00M | $161.00M | +5.0% |
| └─Sotyktu | $100.00M | $80.00M | +26.0% |
| └─Krazati | $58.00M | $53.00M | +10.0% |
| └─Cobenfy | $57.00M | $43.00M | +33.0% |
| └─Other Growth Products | $731.00M | $651.00M | +12.0% |
| └─Total Growth Portfolio | $7.66B | $6.86B | +12.0% |
| └─Eliquis | $4.69B | $3.75B | +25.0% |
| └─Revlimid | $303.00M | $575.00M | -47.0% |
| └─Pomalyst/Imnovid | $130.00M | $675.00M | -81.0% |
| └─Sprycel | $73.00M | $119.00M | -38.0% |
| └─Abraxane | $65.00M | $74.00M | -13.0% |
| └─Other Legacy Products | $154.00M | $177.00M | -13.0% |
| └─Total Legacy Portfolio | $5.42B | $5.37B | +1.0% |
| └─Other Revenue | $(7)M | $0.00K | - |
| GAAP Basic EPS | $1.06 | $1.08 | -1.9% |
| GAAP Diluted EPS | $1.05 | $1.08 | -3.0% |
| Non-GAAP Diluted EPS | $1.35 | $1.63 | -17.0% |
| Net Earnings | $2.16B | $2.19B | -1.5% |
| Net Earnings Attributable to BMS | $2.16B | $2.20B | -1.8% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY2026 Outlook |
|---|---|---|
| Total Revenues | — | ~$49.75B-$50.25B (prev. ~$49.0B-$50.0B) |
| Gross Margin | — | ~69%-70% (prev. ~$69%-70%) |
| Operating Expenses | — | ~$16.5B (prev. ~$16.5B) |
| Other income/(expense) | — | ~($650M) (prev. ~($700M)) |
| Diluted EPS | — | $6.35-$6.55 (prev. $6.75-$7.00) |
| Acquired IPRD Charges & Licensing Income | — | $(0.60) (prev. $(0.02)) |
| WW Revenue Growth | — | 20%-25% (prev. 20%-25%) |
Business Highlights
- ➤FDA approved Zenbexus for previously treated multiple myeloma.
- ➤Phase 3 EXCALIBER-RRMM showed Zenbexus regimen improved progression-free survival.
- ➤FDA approved Camzyos for symptomatic obstructive hypertrophic cardiomyopathy in eligible adults and pediatric patients.
- ➤Phase 3 ACTION-1 met its primary endpoint for RYZ101 in neuroendocrine tumors.
- ➤Phase 3 ALOFT-IPF met its primary endpoint at the 60mg admilparant dose.
- ➤Phase 3 PANKU-Breast01 reported positive interim results for iza-bren.
- ➤BMS announced a $2.3B Houston manufacturing campus expected to create nearly 500 skilled jobs.
- ➤RayzeBio plans a Whitestown, Indiana radiopharmaceutical facility expected to create up to 100 jobs.
Management Commentary
Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb
“We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio. The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones. As we look forward to additional late-stage data in the near term, we remain focused on executing with discipline, investing where we see the greatest opportunity and strengthening the foundation for sustainable growth.”